Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease (NYMC-571)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02675959 |
|
Recruitment Status :
Recruiting
First Posted : February 5, 2016
Last Update Posted : June 21, 2022
|
Sponsor:
New York Medical College
Collaborators:
University of California, Los Angeles
Medical College of Wisconsin
Tufts Medical Center
Baylor College of Medicine
Johns Hopkins University
Dana-Farber Cancer Institute
Children's Hospital Los Angeles
Information provided by (Responsible Party):
Mitchell Cairo, New York Medical College
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | December 2023 |
| Estimated Study Completion Date : | December 2024 |